Rheumatoid Arthritis vs. Osteoarthritis: Key Differences in Pathophysiology, Presentation, and Management

Rheumatoid arthritis (RA) and osteoarthritis (OA) are the two most prevalent forms of arthritis but differ fundamentally in etiology, pathophysiology, and treatment. Accurate differentiation guides appropriate therapy.

Pathophysiology

Feature	Rheumatoid Arthritis (RA)	Osteoarthritis (OA)
Etiology	Autoimmune—loss of tolerance to citrullinated proteins (ACPA), rheumatoid factor (RF)	Mechanical/degenerative—cartilage breakdown from biomechanical stress, aging, metabolic factors
Primary Target	Synovium (pannus formation → cartilage/bone erosion)	Articular cartilage (fibrillation, loss) → subchondral bone sclerosis, osteophytes
Inflammation	Systemic, synovial hyperplasia, cytokines (TNF, IL-6, IL-1, GM-CSF)	Low-grade, secondary to mechanical damage; synovitis variable
Systemic Manifestations	Common: fatigue, fever, weight loss, lung (ILD), heart (pericarditis, CVD), eyes (scleritis), vasculitis, nodules	Generally absent; metabolic syndrome association

Clinical Presentation

Feature	RA	OA
Age of Onset	Any age; peak 30-60	Typically >50; rare <40 without trauma
Sex Ratio	F:M = 3:1	F > M after 55; equal before
Joint Pattern	Symmetrical, small joints (MCP, PIP, wrists, MTP); spares DIP, sacroiliac	Asymmetrical or symmetrical; weight-bearing (knees, hips), DIP, PIP, 1st CMC, spine; spares wrists, elbows, ankles
Morning Stiffness	>1 hour, improves with activity	<30 minutes, worsens with activity
Swelling	Soft, boggy (synovitis); warm	Bony (osteophytes), cool; effusion possible
Deformities	Ulnar deviation, swan-neck, boutonnière, hitchhiker thumb	Heberden (DIP), Bouchard (PIP) nodes; valgus/varus
Extra-Articular	Rheumatoid nodules, vasculitis, ILD, Sicca, Felty	None specific

Diagnostic Workup

• RA: RF, anti-CCP (specific), ESR/CRP, CBC, CMP, baseline X-rays (hands/feet), US/MRI for early synovitis/erosions. 2010 ACR/EULAR classification criteria.
• OA: Clinical diagnosis; X-rays (joint space narrowing, osteophytes, subchondral sclerosis, cysts) confirm. Labs normal (rule out inflammatory).

Treatment Principles

RA: Treat-to-Target (T2T) – Goal: Remission/Low Disease Activity

• csDMARDs: Methotrexate (anchor drug)—start early, escalate dose. Leflunomide, sulfasalazine, hydroxychloroquine.
• bDMARDs: TNF inhibitors (adalimumab, etanercept), IL-6R inhibitors (tocilizumab), CTLA4-Ig (abatacept), anti-CD20 (rituximab), JAK inhibitors (tofacitinib, upadacitinib, baricitinib)—after csDMARD failure.
• tsDMARDs: JAK inhibitors (oral).
• Glucocorticoids: Bridge therapy (prednisone ≤10 mg/day); taper ASAP.
• NSAIDs: Symptomatic only.
• Monitoring: DAS28/CDAI/SDAI every 1-3 months; LFTs, CBC, CXR (methotrexate).

OA: Symptom Management & Joint Preservation

• Non-Pharmacologic (Core): Exercise (aerobic + strengthening), weight loss (if overweight—5-10% reduces pain significantly), PT/OT, assistive devices, braces, thermal modalities.
• Pharmacologic: Topical NSAIDs (first-line knee/hand), oral NSAIDs (lowest dose, shortest duration, PPI co-therapy if GI risk), acetaminophen (limited efficacy), duloxetine (chronic pain), intra-articular corticosteroids (flare), hyaluronic acid (controversial).
• Surgical: Arthroscopy (mechanical symptoms only), osteotomy (young, malalignment), joint replacement (end-stage, failed conservative).

Key Differentiators Summary

• RA = inflammatory, symmetric, small joints, prolonged AM stiffness, systemic, autoantibodies → immunosuppression
• OA = mechanical, weight-bearing/DIP, brief stiffness, bony enlargement, no autoantibodies → exercise, weight loss, NSAIDs, joint replacement
• Overlap possible (e.g., RA patient develops OA); clinical judgment required.

When to Refer to Rheumatology

• Suspected inflammatory arthritis (prolonged stiffness, symmetric small joints, systemic symptoms)
• Positive RF/anti-CCP with joint symptoms
• RA not controlled on csDMARDs
• Diagnostic uncertainty